Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Type of study
Publication year range
1.
PLoS One ; 8(1): e53698, 2013.
Article in English | MEDLINE | ID: mdl-23341978

ABSTRACT

Loss of thymidine kinase 2 (TK2) causes a heterogeneous myopathic form of mitochondrial DNA (mtDNA) depletion syndrome (MDS) in humans that predominantly affects skeletal muscle tissue. In mice, TK2 deficiency also affects several tissues in addition to skeletal muscle, including brain, heart, adipose tissue, kidneys and causes death about 3 weeks after birth. We analysed skeletal muscle and heart muscle tissues of Tk2 knockout mice at postnatal development phase and observed that TK2 deficient pups grew slower and their skeletal muscles appeared significantly underdeveloped, whereas heart was close to normal in size. Both tissues showed mtDNA depletion and mitochondria with altered ultrastructure, as revealed by transmission electron microscopy. Gene expression microarray analysis showed a strong down-regulation of genes involved in cell cycle and cell proliferation in both tissues, suggesting a lower pool of undifferentiated proliferating cells. Analysis of isolated primary myoblasts from Tk2 knockout mice showed slow proliferation, less ability to differentiate and signs of premature senescence, even in absence of mtDNA depletion. Our data demonstrate that TK2 deficiency disturbs myogenic progenitor cells function in postnatal skeletal muscle and we propose this as one of the causes of underdeveloped phenotype and myopathic characteristic of the TK2 deficient mice, in addition to the progressive mtDNA depletion, mitochondrial damage and respiratory chain deficiency in post-mitotic differentiated tissue.


Subject(s)
Gene Expression Regulation, Developmental , Muscle Development , Muscle, Skeletal/cytology , Muscle, Skeletal/growth & development , Stem Cells/cytology , Thymidine Kinase/deficiency , Animals , Cell Cycle , Cell Differentiation , Cell Proliferation , DNA, Mitochondrial/metabolism , Female , Gene Expression Profiling , Gene Knockout Techniques , Hindlimb , Male , Mice , Mitochondria/metabolism , Muscle, Skeletal/enzymology , Muscle, Skeletal/metabolism , Myoblasts/cytology , Myoblasts/metabolism , Myocardium/cytology , Myocardium/enzymology , Myocardium/metabolism , Phenotype , Stem Cells/metabolism , Thymidine Kinase/genetics
2.
Retrovirology ; 7: 20, 2010 Mar 15.
Article in English | MEDLINE | ID: mdl-20230608

ABSTRACT

BACKGROUND: The synthetic peptide glycyl-prolyl-glycine amide (GPG-NH2) was previously shown to abolish the ability of HIV-1 particles to fuse with the target cells, by reducing the content of the viral envelope glycoprotein (Env) in progeny HIV-1 particles. The loss of Env was found to result from GPG-NH2 targeting the Env precursor protein gp160 to the ER-associated protein degradation (ERAD) pathway during its maturation. However, the anti-viral effect of GPG-NH2 has been shown to be mediated by its metabolite alpha-hydroxy-glycineamide (alphaHGA), which is produced in the presence of fetal bovine serum, but not human serum. In accordance, we wanted to investigate whether the targeting of gp160 to the ERAD pathway by GPG-NH2 was attributed to its metabolite alphaHGA. RESULTS: In the presence of fetal bovine serum, GPG-NH2, its intermediary metabolite glycine amide (G-NH2), and final metabolite alphaHGA all induced the degradation of gp160 through the ERAD pathway. However, when fetal bovine serum was replaced with human serum only alphaHGA showed an effect on gp160, and this activity was further shown to be completely independent of serum. This indicated that GPG-NH2 acts as a pro-drug, which was supported by the observation that it had to be added earlier to the cell cultures than alphaHGA to induce the degradation of gp160. Furthermore, the substantial reduction of Env incorporation into HIV-1 particles that occurs during GPG-NH2 treatment was also achieved by treating HIV-1 infected cells with alphaHGA. CONCLUSIONS: The previously observed specificity of GPG-NH2 towards gp160 in HIV-1 infected cells, resulting in the production of Env (gp120/gp41) deficient fusion incompetent HIV-1 particles, was most probably due to the action of the GPG-NH2 metabolite alphaHGA.


Subject(s)
Anti-HIV Agents/pharmacology , Endoplasmic Reticulum/metabolism , HIV-1/drug effects , Oligopeptides/pharmacology , Prodrugs/pharmacology , env Gene Products, Human Immunodeficiency Virus/metabolism , Animals , Anti-HIV Agents/metabolism , Cattle , Humans , Oligopeptides/metabolism , Prodrugs/metabolism , Serum/virology
3.
Retrovirology ; 6: 34, 2009 Apr 08.
Article in English | MEDLINE | ID: mdl-19356241

ABSTRACT

BACKGROUND: Formation of an HIV-1 particle with a conical core structure is a prerequisite for the subsequent infectivity of the virus particle. We have previously described that glycineamide (G-NH2) when added to the culture medium of infected cells induces non-infectious HIV-1 particles with aberrant core structures. RESULTS: Here we demonstrate that it is not G-NH2 itself but a metabolite thereof that displays antiviral activity. We show that conversion of G-NH2 to its antiviral metabolite is catalyzed by an enzyme present in bovine and porcine but surprisingly not in human serum. Structure determination by NMR suggested that the active G-NH2 metabolite was alpha-hydroxy-glycineamide (alpha-HGA). Chemically synthesized alpha-HGA inhibited HIV-1 replication to the same degree as G-NH2, unlike a number of other synthesized analogues of G-NH2 which had no effect on HIV-1 replication. Comparisons by capillary electrophoresis and HPLC of the metabolite with the chemically synthesized alpha-HGA further confirmed that the antiviral G-NH2-metabolite indeed was alpha-HGA. CONCLUSION: alpha-HGA has an unusually simple structure and a novel mechanism of antiviral action. Thus, alpha-HGA could be a lead for new antiviral substances belonging to a new class of anti-HIV drugs, i.e. capsid assembly inhibitors.


Subject(s)
Anti-HIV Agents , Capsid/drug effects , Glycine/analogs & derivatives , HIV-1/drug effects , Serum/chemistry , Animals , Anti-HIV Agents/chemistry , Anti-HIV Agents/isolation & purification , Anti-HIV Agents/metabolism , Anti-HIV Agents/pharmacology , Capsid/chemistry , Capsid/metabolism , Capsid Proteins/metabolism , Cattle , Cell Line , Glycine/chemistry , Glycine/isolation & purification , Glycine/metabolism , Glycine/pharmacology , HIV-1/physiology , Humans , Serum/metabolism , Structure-Activity Relationship , Swine , Virion/metabolism , Virus Replication/drug effects
4.
Antimicrob Agents Chemother ; 52(10): 3737-44, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18644965

ABSTRACT

Upon maturation of the human immunodeficiency virus type 1 (HIV-1) virion, proteolytic cleavage of the Gag precursor protein by the viral protease is followed by morphological changes of the capsid protein p24, which will ultimately transform the virus core from an immature spherical to a mature conical structure. Virion infectivity is critically dependent on the optimal semistability of the capsid cone structure. We have reported earlier that glycineamide (G-NH(2)), when added to the culture medium of infected cells, inhibits HIV-1 replication and that HIV-1 particles with aberrant core structures were formed. Here we show that it is not G-NH(2) itself but a metabolite thereof, alpha-hydroxy-glycineamide (alpha-HGA), that is responsible for the antiviral activity. We show that alpha-HGA inhibits the replication of clinical HIV-1 isolates with acquired resistance to reverse transcriptase and protease inhibitors but has no effect on the replication of any of 10 different RNA and DNA viruses. alpha-HGA affected the ability of the HIV-1 capsid protein to assemble into tubular or core structures in vitro and in vivo, probably by binding to the hinge region between the N- and C-terminal domains of the HIV-1 capsid protein as indicated by matrix-assisted laser desorption ionization-mass spectrometry results. As an antiviral compound, alpha-HGA has an unusually simple structure, a pronounced antiviral specificity, and a novel mechanism of antiviral action. As such, it might prove to be a lead compound for a new class of anti-HIV substances.


Subject(s)
Anti-HIV Agents/pharmacology , Glycine/analogs & derivatives , HIV-1/drug effects , Capsid Proteins/physiology , Drug Resistance, Viral/genetics , Glycine/pharmacology , HIV Core Protein p24/drug effects , HIV Core Protein p24/genetics , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/genetics , HIV-1/pathogenicity , HIV-1/physiology , HeLa Cells , Humans , In Vitro Techniques , Microbial Sensitivity Tests , Microscopy, Electron, Transmission , Mutation , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Virulence/drug effects , Virus Assembly/drug effects , Virus Replication/drug effects
5.
Retrovirology ; 4: 69, 2007 Sep 28.
Article in English | MEDLINE | ID: mdl-17903253

ABSTRACT

BACKGROUND: The mature HIV-1 conical core formation proceeds through highly regulated protease cleavage of the Gag precursor, which ultimately leads to substantial rearrangements of the capsid (CAp24) molecule involving both inter- and intra-molecular contacts of the CAp24 molecules. In this aspect, Asp51 which is located in the N-terminal domain of HIV-1 CAp24 plays an important role by forming a salt-bridge with the free imino terminus Pro1 following proteolytic cleavage and liberation of the CAp24 protein from the Pr55Gag precursor. Thus, previous substitution mutation of Asp51 to alanine (D51A) has shown to be lethal and that this invariable residue was found essential for tube formation in vitro, virus replication and virus capsid formation. RESULTS: We extended the above investigation by introducing three different D51 substitution mutations (D51N, D51E, and D51Q) into both prokaryotic and eukaryotic expression systems and studied their effects on in vitro capsid assembly and virus infectivity. Two substitution mutations (D51E and D51N) had no substantial effect on in vitro capsid assembly, yet they impaired viral infectivity and particle production. In contrast, the D51Q mutant was defective both for in vitro capsid assembly and for virus replication in cell culture. CONCLUSION: These results show that substitutions of D51 with glutamate, glutamine, or asparagine, three amino acid residues that are structurally related to aspartate, could partially rescue both in vitro capsid assembly and intra-cellular CAp24 production but not replication of the virus in cultured cells.


Subject(s)
Capsid Proteins/genetics , HIV-1/genetics , Virus Assembly/physiology , Virus Diseases/genetics , Amino Acid Substitution , Capsid Proteins/chemistry , Capsid Proteins/physiology , Cells, Cultured , HIV-1/physiology , Humans , Mutation , Virus Replication
6.
Retrovirology ; 4: 19, 2007 Mar 19.
Article in English | MEDLINE | ID: mdl-17371591

ABSTRACT

We have studied the effects associated with two single amino acid substitution mutations in HIV-1 capsid (CA), the E98A and E187G. Both amino acids are well conserved among all major HIV-1 subtypes. HIV-1 infectivity is critically dependent on proper CA cone formation and mutations in CA are lethal when they inhibit CA assembly by destabilizing the intra and/or inter molecular CA contacts, which ultimately abrogate viral replication. Glu98, which is located on a surface of a flexible cyclophilin A binding loop is not involved in any intra-molecular contacts with other CA residues. In contrast, Glu187 has extensive intra-molecular contacts with eight other CA residues. Additionally, Glu187 has been shown to form a salt-bridge with Arg18 of another N-terminal CA monomer in a N-C dimer. However, despite proper virus release, glycoprotein incorporation and Gag processing, electron microscopy analysis revealed that, in contrast to the E187G mutant, only the E98A particles had aberrant core morphology that resulted in loss of infectivity.


Subject(s)
Amino Acid Substitution , Capsid Proteins/chemistry , Cyclophilin A/metabolism , HIV-1/genetics , HIV-1/pathogenicity , Virus Assembly , Animals , Binding Sites/genetics , Capsid/metabolism , Capsid Proteins/genetics , Capsid Proteins/metabolism , Cell Line , HIV-1/metabolism , HIV-1/ultrastructure , HeLa Cells , Humans , Microscopy, Electron, Transmission , Rabbits , Structure-Activity Relationship , Virion/ultrastructure
7.
J Virol ; 79(9): 5557-67, 2005 May.
Article in English | MEDLINE | ID: mdl-15827170

ABSTRACT

Heat shock protein 70 (Hsp70) is incorporated within the membrane of primate lentiviral virions. Here we demonstrate that Hsp70 is also incorporated into oncoretroviral virions and that it remains associated with membrane-stripped human immunodeficiency virus type 1 (HIV-1) virion cores. To determine if Hsp70 promotes virion infectivity, we attempted to generate Hsp70-deficient virions with gag deletion mutations, Hsp70 transdominant mutants, or RNA interference, but these efforts were confounded, largely because they disrupt virion assembly. Given that polypeptide substrates are bound and released by Hsp70 in an ATP-hydrolytic reaction cycle, we supposed that incubation of HIV-1 virions with ATP would perturb Hsp70 interaction with substrates in the virion and thereby decrease infectivity. Treatment with ATP or ADP had no observable effect, but ATPgammaS and GTPgammaS, nucleotide triphosphate analogues resistant to Hsp70 hydrolysis, dramatically reduced the infectivity of HIV-1 and murine leukemia virus virions. ATPgammaS-treated virions were competent for fusion with susceptible target cells, but viral cDNA synthesis was inhibited to an extent that correlated with the magnitude of decrease in infectivity. Intravirion reverse transcription by HIV-1, simian immunodeficiency virus, or murine leukemia virus was also inhibited by ATPgammaS. The effects of ATPgammaS on HIV-1 reverse transcription appeared to be indirect, resulting from disruption of virion core morphology that was evident by transmission electron microscopy. Consistent with effects on capsid conformation, ATPgammaS-treated viruslike particles failed to saturate host antiviral restriction activity. Our observations support a model in which the catalytic activity of virion-associated Hsp70 is required to maintain structural integrity of the virion core.


Subject(s)
Adenosine Triphosphate/analogs & derivatives , Adenosine Triphosphate/pharmacology , HIV-1/physiology , Leukemia Virus, Murine/chemistry , Virion/physiology , Animals , Cell Line , Gene Deletion , Genes, gag/genetics , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , HIV Infections/virology , HIV Reverse Transcriptase/antagonists & inhibitors , HIV-1/chemistry , HIV-1/pathogenicity , HIV-1/ultrastructure , HSP70 Heat-Shock Proteins/deficiency , HSP70 Heat-Shock Proteins/genetics , Humans , Leukemia Virus, Murine/genetics , Rats , Retroviridae Infections/virology , Reverse Transcriptase Inhibitors/pharmacology , Tumor Virus Infections/virology , Virion/chemistry , Virion/ultrastructure , Virulence , Virus Assembly
8.
Antimicrob Agents Chemother ; 49(1): 40-4, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15616273

ABSTRACT

The chemically modified tripeptide glycyl-prolyl-glycine-amide (GPG-NH(2)) inhibits replication of human immunodeficiency virus (HIV) type 1 (HIV-1) in vitro, probably by interfering with capsid formation. The aim of the present study was to determine whether the metabolites glycyl-proline (GP-OH), glycine (G-OH), prolyl-glycine-amide (PG-NH(2)), proline (P-OH), and glycine-amide (G-NH(2)) from proteolytic cleavage may inhibit the replication of HIV-1 in vitro. PG-NH(2) has previously been shown to have a modest effect on HIV-1 replication. In the present study we show that G-NH(2) exhibits a pronounced inhibitory effect on HIV-1. This effect was not due to a decrease in cell proliferation or viability and could not be shown for herpes simplex virus type 1. The G-NH(2) concentration that inhibited virus replication by 50% (IC(50)) was equimolar to that of GPG-NH(2) and ranged from 3 to 41 microM. Transmission electron microscopy revealed that the effect of G-NH(2) on HIV-1 morphology was equivalent to that of GPG-NH(2) and showed disarranged capsid structures, indicating interference with capsid formation. Serial passage of HIV-infected cells with G-NH(2) for more than 20 subcultivations did not decrease the susceptibility to the compound. The results from this study suggest that GPG-NH(2) might act as a prodrug and that G-NH(2) is an active antiretroviral metabolite.


Subject(s)
Anti-HIV Agents/pharmacology , Glycine/analogs & derivatives , Glycine/pharmacology , HIV-1/drug effects , Oligopeptides/pharmacology , Animals , Cell Line , Cells, Cultured , Drug Resistance, Viral , HIV-1/physiology , Humans , Leukocytes, Mononuclear/virology , Microbial Sensitivity Tests , Oligopeptides/metabolism , Serial Passage , Virus Assembly/drug effects , Virus Replication/drug effects
9.
J Gen Virol ; 85(Pt 10): 2903-2913, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15448352

ABSTRACT

The capsid protein (CA or p24) of human immunodeficiency virus type 1 (HIV-1) plays a major role both early and late in the virus replication cycle. Many studies have suggested that the C-terminal domain of this protein is involved in dimerization and proper assembly of the viral core. Point mutations were introduced in two conserved sites of this region and their effects on viral protein expression, particle assembly and infectivity were studied. Eight different mutants (L205A+P207A, L205A, P207A, 223GPG225AAA, G223A, P224A, G225A and V221G) of the infectious clone pNL4-3 were constructed. Most substitutions had no substantial effect on HIV-1 protein synthesis, yet they impaired viral infectivity and particle production. The two mutants P207A and V221G also had a profound effect on Gag-Pol protein processing in HeLa-tat cells. However, these results were cell line-specific and Gag-Pol processing of P207A was not affected in 293T cells. In HeLa-tat cells, no virus particles were detected with the P207A mutation, whereas the other mutant virus particles were heterogeneous in size and morphology. None of the mutants showed normal, mature, conical core structures in HeLa-tat cells. These results indicate that the two conserved sequences in the C-terminal CA domain are essential for proper morphogenesis and infectivity of HIV-1 particles.


Subject(s)
Capsid Proteins/chemistry , HIV-1/physiology , Virus Assembly , Amino Acid Sequence , Amino Acid Substitution , Animals , Capsid Proteins/physiology , Conserved Sequence , Fluorescent Antibody Technique , Gene Products, gag/analysis , HIV Core Protein p24/analysis , HIV Core Protein p24/chemistry , HIV-1/ultrastructure , Molecular Sequence Data , Protein Precursors/analysis , Rabbits , Structure-Activity Relationship , Virion/ultrastructure
10.
Antimicrob Agents Chemother ; 46(11): 3597-605, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12384371

ABSTRACT

Capsid assembly during virus replication is a potential target for antiviral therapy. The Gag polyprotein is the main structural component of retroviral particles, and in human immunodeficiency virus type 1 (HIV-1), it contains the sequences for the matrix, capsid, nucleocapsid, and several small polypeptides. Here, we report that at a concentration of 100 micro M, 7 of 83 tripeptide amides from the carboxyl-terminal sequence of the HIV-1 capsid protein p24 suppressed HIV-1 replication (>80%). The three most potent tripeptides, glycyl-prolyl-glycine-amide (GPG-NH(2)), alanyl-leucyl-glycine-amide (ALG-NH(2)), and arginyl-glutaminyl-glycine-amide (RQG-NH(2)), were found to interact with p24. With electron microscopy, disarranged core structures of HIV-1 progeny were extensively observed when the cells were treated with GPG-NH(2) and ALG-NH(2). Furthermore, nodular structures of approximately the same size as the broad end of HIV-1 conical capsids were observed at the plasma membranes of treated cells only, possibly indicating an arrest of the budding process. Corresponding tripeptides with nonamidated carboxyl termini were not biologically active and did not interact with p24.


Subject(s)
HIV-1/growth & development , Oligopeptides/pharmacology , Capsid Proteins/metabolism , Cells, Cultured , Electrophoresis, Capillary , HIV Core Protein p24/metabolism , HIV-1/drug effects , Humans , Microscopy, Electron , Morphogenesis/drug effects , Oligopeptides/chemical synthesis , Virus Replication/drug effects
11.
Microbiology (Reading) ; 145 ( Pt 5): 1253-1262, 1999 May.
Article in English | MEDLINE | ID: mdl-10376842

ABSTRACT

Six genes involved in cellulose synthesis in Rhizobium leguminosarum bv. trifolii were identified using Tn5 mutagenesis. Four of them displayed homology to the previously cloned and sequenced Agrobacterium tumefaciens cellulose genes celA, celB, celC and celE. These genes are organized similarly in R. leguminosarum bv. trifolii. In addition, there were strong indications that two tandemly located genes, celR1 and celR2, probably organized as one operon, are involved in the regulation of cellulose synthesis. The deduced amino acid sequences of these genes displayed a high degree of similarity to the Caulobacter crescentus DivK and PleD proteins that belong to the family of two-component response regulators. This is to our knowledge the first report of genes involved in the regulation of cellulose synthesis. Results from attachment assays and electron microscopic studies indicated that cellulose synthesis in R. leguminosarum bv. trifolii is induced upon close contact with plant roots during the attachment process.


Subject(s)
Cellulose/biosynthesis , Genes, Bacterial , Genes, Regulator , Rhizobium leguminosarum/genetics , Amino Acid Sequence , DNA Transposable Elements , Fabaceae/microbiology , Gene Expression Regulation, Bacterial , Genetic Complementation Test , Molecular Sequence Data , Mutagenesis, Insertional , Plants, Medicinal , Rhizobium leguminosarum/growth & development , Rhizobium leguminosarum/metabolism , Sequence Alignment , Sequence Analysis, DNA
SELECTION OF CITATIONS
SEARCH DETAIL
...